Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06304194 | RECRUITING | Oncologic Disease

Molecular Characterizazion and Biological Samples Centralisation of Patients Affected by Oncoematolofic Pathology
Sponsor:

Meyer Children's Hospital IRCCS

Information provided by (Responsible Party):

Marinella Veltroni

Brief Summary:

Currently, the molecular characterization of onco-hematological, onco-immunological and hematological diseases, at onset or in relapse, of patients with suspected diagnosis afferent to the CROP centers, is done through centralization of biological samples at reference laboratories outside the Tuscany Region. In order to preserve the wealth of clinical and biological data and use it for the benefit of present and future patients treated at the CROP centers, it is useful to evaluate the feasibility of centralization and molecular typing of mutations present in tumor tissue at the IRCCS AOU Meyer Oncohematology Laboratories and subsequently the analysis of clinical data from patients with diseases not under study to lay the foundations of a translational database that can then be associated with a biobank in the future. This will enable a targeted contribution to pediatric oncohematology research, investing in possible targeted therapies with those patient subgroups that benefit from personalized disease assessment in mind. The goal of the project is to improve the regional infrastructure dedicated to organized data collection and management of biological samples in adequate time resulting in better and more comprehensive data collection.

Condition or disease

Oncologic Disease

Hematologic Diseases

Intervention/treatment

Analysis of biological samples

Phase

NA

Study Type : INTERVENTIONAL
Estimated Enrollment : 340 participants
Masking : NONE
Primary Purpose : SCREENING
Official Title : Pilot Study to Assess the Feasibility of Centralizing Biological Samples at Onset and Relapse of Patients Referred to CROP Centers for Molecular Characterization of Oncohematologic Pathology
Actual Study Start Date : 2023-07-05
Estimated Primary Completion Date : 2027-07-05
Estimated Study Completion Date : 2028-07-05

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 0 Years to 30 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Diagnostic suspicion of oncologic, hematologic or onco-immunologic disease
  • * Suspected recurrence of oncological, onco-hematological, hematological or onco -immunological disease
  • * Availability of biological material
  • * Signature of informed consent
  • * Age between 0 and 30 years
Exclusion Criteria
  • * Failure to sign the consent
  • * Insufficiency of biological material for analysis
  • * Patients with HIV, HCV and HBV seropositivity (HBSAg) due to biohazard and bias related to patients' immunological status that could influence gene expression and tumor behavior.
Molecular Characterizazion and Biological Samples Centralisation of Patients Affected by Oncoematolofic Pathology

Location Details

NCT06304194

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

Italy,

Meyer Children's Hospital IRCCS

Florence, Italy,

RECRUITING

Italy,

Pisan University Hospital Company

Pisa, Italy,

RECRUITING

Italy,

Siena University Hospital Company

Siena, Italy,